Skip to Content

Hypovase 0.5 mg tablets – Deletion of all indications of paediatric use of prazosin

08/03/2024
Medicines for human use Product information update (PIU)

This update is to inform healthcare professionals of a recent update to the product information for Hypovase 0.5 mg tablets, (prazosin hydrochloride). This update relates to the deletion all indications of paediatric use of prazosin in the Summary of Product Characteristics and Patient Information Leaflet.

Please see the document linked below for further information.

Product information

Active substance
Prazosin hydrochloride
Authorisation holder
Pfizer Healthcare Ireland
Authorisation number
PA0822/195/001
Human or veterinary medicine
Human Medicine

Documents

Opens in new window Hypovase 0.5 mg tablets Product Information Update 16 February 2024 PDF : 131KB | 01/11/2024